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Abstract
Preterm and young neonates are prone to inadequate surfactant production and are susceptible to respiratory
distress syndrome characterized by alveolar damage and hyaline-membrane formation. Glucocorticoid
therapy is commonly used in preterm and young infants to enhance lung maturation and surfactant synthesis.
Recently, vascular endothelial growth factor (VEGF) was suggested to be a novel therapeutic agent for lung
maturation that lacked adverse effects in mice. The purpose of this study was to assess the safety of
incremental concentration (0.0005, 0.005, and 0.05 mg/ml) and duration (16, 24, and 32 hours) of
recombinant human VEGF after bronchoscopic instillation (10 ml) in neonatal lambs. High-dose VEGF
caused locally extensive plum-red consolidation that was microscopically characterized by interstitial and
alveolar infiltrates of cells that were morphologically and phenotypically (CD68+) consistent with
monocytes/macrophages. T cells (CD3+) and B cells (CD79+) were located primarily in bronchus/
bronchiole-associated lymphoid tissue and were not consistently altered by treatment with VEGF. The dose of
VEGF had significant effects on both gross lesions (P < .0047) and microscopic monocyte/macrophage
recruitment scores (P < .0001). Thus, the VEGF dose instilled into the lung greatly influenced cellular
recruitment and lesion development. The post-dosing interval of VEGF in this study had minor impact (no
statistical significance) on cellular recruitment. This study showed that airway deposition of VEGF in the
neonatal lamb induces monocyte/macrophage recruitment to the lung and high doses can cause severe
lesions. The cellular recruitment suggests further research is needed to define dosages that are efficacious in
enhancing lung maturation while minimizing potential adverse effects.
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Abstract
Preterm and young neonates are prone to inadequate surfactant production and are susceptible to
respiratory distress syndrome characterized by alveolar damage and hyaline-membrane formation.
Glucocorticoid therapy is commonly used in preterm and young infants to enhance lung maturation
and surfactant synthesis. Recently, vascular endothelial growth factor (VEGF) was suggested to be
a novel therapeutic agent for lung maturation that lacked adverse effects in mice. The purpose of this
study was to assess the safety of incremental concentration (0.0005, 0.005, and 0.05 mg/ml) and
duration (16, 24, and 32 hours) of recombinant human VEGF after bronchoscopic instillation (10
ml) in neonatal lambs. High-dose VEGF caused locally extensive plum-red consolidation that was
microscopically characterized by interstitial and alveolar infiltrates of cells that were
morphologically and phenotypically (CD68+) consistent with monocytes/macrophages. T cells
(CD3+) and B cells (CD79+) were located primarily in bronchus/bronchiole-associated lymphoid
tissue and were not consistently altered by treatment with VEGF. The dose of VEGF had significant
effects on both gross lesions (P < .0047) and microscopic monocyte/macrophage recruitment scores
(P < .0001). Thus, the VEGF dose instilled into the lung greatly influenced cellular recruitment and
lesion development. The post-dosing interval of VEGF in this study had minor impact (no statistical
significance) on cellular recruitment. This study showed that airway deposition of VEGF in the
neonatal lamb induces monocyte/macrophage recruitment to the lung and high doses can cause severe
lesions. The cellular recruitment suggests further research is needed to define dosages that are
efficacious in enhancing lung maturation while minimizing potential adverse effects.
Keywords
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Preterm and young infants are at increased risk for respiratory distress syndrome (RDS)
associated with inadequate surfactant expression. A lack of surfactant causes increased alveolar
surface tension, hypoventilation/hypoxemia, and progression to cellular injury with the
characteristic fibrinonecrotic exudate in alveolar lumens.21 Surfactant replacement is
recognized as an effective prophylactic therapy for RDS, and glucocorticoids are often used
pre- and postnatally in infants to stimulate lung growth and surfactant development. 5,22
Request reprints from David Meyerholz, Department of Pathology, University of Iowa Carver College of Medicine, 145 Medical Research
Center, Iowa City, IA 52242. david-meyerholz@uiowa.edu.
NIH Public Access
Author Manuscript
Vet Pathol. Author manuscript; available in PMC 2009 December 9.
Published in final edited form as:
Vet Pathol. 2006 September ; 43(5): 689–694. doi:10.1354/vp.43-5-689.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
However, neonatal glucocorticoid administration has been associated with adverse effects,
including the following: hypertension, infection, gastrointestinal bleeding or perforation,
hypertrophic cardiomyopathy, and lung and neural developmental abnormalities.5,11,13,24,25,
30 The potential for adverse effects has prompted efforts to identify novel agents to stimulate
lung maturation while minimizing the potential for adverse effects.
Vascular endothelial growth factor (VEGF) is well recognized as an important regulator of
vasculogenesis and angiogenesis.7,10 However, in the lung, VEGF has additional functions,
including stimulation of airway epithelial-cell proliferation and enhancing surfactant protein
(SP)-A and SP-C mRNA expression.6 Recently, VEGF was given to preterm mice as a novel
therapy for RDS.8 Intratracheal VEGF treatment enhanced lung maturation and increased the
percentage of preterm pup survival, whereas adverse effects, such as neovascularization or
pulmonary edema, were not evident.
The lamb model is often used in the study of perinatal lung development and disease.12,23 The
purpose of this study was to characterize the safety of variable VEGF dose and time after
instillation in the neonatal lamb model for future extrapolation to the preterm lamb model.
Materials and Methods
Animals
Healthy neonatal lambs (2–4 days of age) were acquired through Iowa State University’s
Laboratory Animal Resources (Table 1), housed indoors in a temperature-controlled
environment and grouped together in a pen. All procedures were approved by the animal care
and use committee. Body temperatures of lambs were taken to further ensure the health status
of the lambs. Antibiotic (ceftiofur 2.2 mg/kg/day, intramuscular) was administered during the
course of the experiment to minimize potential for complications with bacterial pneumonia.
Each lamb was given xylazine (0.1 mg/kg) intravenously (IV) for sedation and was placed in
right lateral recumbency. A sterile bronchoscope was used to instill 10 ml sterile saline solution,
recombinant human VEGF (0.05, 0.005, or 0.0005 mg/ml; endotoxin <100 pg/µg in stock
solution; diluted with sterile saline solution and titrated to pH of 7.0; Catalog #PR2951A;
Invitrogen, Carlsbad, CA, USA) or bovine serum albumin (BSA, 0.1 mg/ml) into the right
mainstem bronchus just past the tracheal bifurcation. The lamb remained in right lateral
recumbency for another 10 minutes and was given tolazoline (3 mg/kg, IV slowly) to reverse
the sedation. During the postinstillation period and before euthanasia, no evidence of
respiratory distress or alteration was noted. At the appropriate time point after instillation (16,
24, or 32 hours), each lamb was euthanized with IV sodium pentobarbital.
Tissues
Lungs were removed from the thoracic cavity, examined for lesions at site of bronchoscopic
deposition, and given a lesion score of “−” (no lesion), “+” (mild, earliest detectable plum-red
discoloration), “++” (moderate, distinct plum-red discoloration and more firm to touch than
adjacent normal lung), or “+++” (severe, distinct raised, plum-red discoloration with
consolidation). Tissue sections were collected bilaterally from the cranial, middle, and caudal
lobes (1 slide per region), placed in 10% neutral-buffered formalin, and processed routinely
for hematoxylin and eosin (HE) staining or immunohistochemistry.
Immunohistochemistry
Sections (6-µm thick) were deparaffinized through a series of ethanol baths and washed (Tris-
buffered saline solution, pH 7.6, 0.1 M). These were immersed in a 1% trypsin solution for 40
minutes and then washed 3 times. Slides were then placed in a solution of 10% normal sheep
serum per 10% normal goat serum in phosphate-buffered saline solution (PBS). The sections
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were then placed in primary antibody solutions (4°C for 72 hours) against either CD68 (1 : 300
mouse monoclonal anti-CD68, Dakocytomation Inc., Carpinteria, CA, USA), CD3 (1:100
mouse monoclonal anti-CD3; Dakocytomation), or CD79 (1:100 mouse monoclonal anti-
CD79-alpha; Dakocytomation) and then washed multiple times. Endogenous peroxidase was
blocked with 3% hydrogen peroxide in PBS (40 minutes) followed by multiple washes. The
sections were then immersed in the biotinylated secondary antibody (1 : 300 goat polyclonal
anti-mouse; Dakocytomation; 45 minutes) solution, washed (3 times), placed in streptavidin
conjugated horseradish peroxidase solution (Vector Laboratories Inc., Burlingame, CA, USA;
45 minutes), washed (3 times) and exposed to chromogen (Vector red; Vector Laboratories).
The slides were counter stained in Harris hematoxylin, dehydrated through a series of ethanol
baths and cover slipped.
Morphometry
Sections of right cranial and middle lung lobes (sites of treatment deposition) were compared
with the control (saline solution and BSA) lungs. A pathologist (blinded, without knowledge
of treatment status) characterized the morphology of the infiltrating leukocyte populations and
scored the cellular infiltrate in the treated areas as 1, within normal limits; 2, mild thickening
of alveolar septa by monocyte infiltration, with infrequent macrophages in alveolar lumens; 3,
thickening of alveolar septa by monocyte/macrophage infiltration, with increased numbers of
macrophages in alveolar lumens; or 4, sheets of monocytes/macrophages fill alveolar lumens
and interstitial spaces. Each section was scored twice and the average score recorded.
Statistics
The means for each group interaction (time and dose) were determined for both gross lesion
scores and monocyte/macrophage recruitment scores and then were transformed to a
logarithmic scale. Transformed mean scores were analyzed by an unreplicated 2-way analysis
of variance. Significance was determined to be at P < .05.
Results
Sterile saline solution was used as a procedural control and BSA (at 10 times the VEGF
concentration) was used as a nonspecific protein control. At necropsy, lungs, which had been
infused with sterile saline solution and BSA, lacked gross and microscopic lesions. Lungs
contralateral to the infusion site lacked gross and microscopic lesions in all cases. Gross lesions
that consisted of mild multifocal to locally extensive plum-red congestion of the right cranial/
middle lobes were seen in VEGF-treated lambs 8, 11, 12, 14, and 15 (Table 1). Lung of lamb
No. 13 had increased plum-red coloration and was slightly firm to the touch compared with
the adjacent normal lung. Lung of lamb No. 16 had a locally extensive, well-demarcated plum-
red, slightly raised lesion in the right cranial/middle lobes and was firm to the touch. The VEGF
dose had a significant effect (P < .0047) on the gross lesion scores.
Microscopically, affected lungs had a cellular infiltrate in the alveolar lumen and septa that
generally increased in severity according to the VEGF dosage. The cellular infiltrate was
composed predominantly (~95%) of cells morphologically and phenotypically (CD68+)
consistent with monocytes/macrophages (Fig. 1–3). T cells (CD3+) and B cells (CD79+) were
localized primarily to aggregates surrounding airways, consistent with bronchus/bronchiole-
associated lymphoid tissue, and the number of these cells was not consistently increased. Small
numbers of neutrophils were seen in the alveolar septa. The microscopic cellular infiltration
(monocytes/macrophages) score was significantly affected by the VEGF dose (P < .0001). The
post-dosing interval of VEGF treatment produced minor (no statistical significance) alteration
in the monocyte/macrophage recruitment.
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Discussion
The potential use of VEGF as a novel and safe perinatal therapy for RDS was recently suggested
in preterm mice, and this created much interest for eventual use in pediatric patients.1,8,26 An
appealing aspect of the VEGF therapy was the apparent lack of lesions and adverse effects, an
important consideration when comparing VEGF with glucocorticoid therapy, which has
documented short- and long-term adverse effects.5 In this study, bronchoscopic deposition of
VEGF-induced monocyte/macrophage recruitment that progressively increased with the dose
of VEGF. The high doses caused severe monocytic/macrophagic pneumonitis, with gross and
microscopic lesions. The cellular infiltration was lacking in the sterile saline solution or BSA
(nonspecific protein) group controls, as well as in all lamb lungs contralateral to the instillation
site. The acute monocyte/macrophage recruitment was not consistent with cellular recruitment
after antigen deposition in lung and was not consistent with any spontaneous natural respiratory
disease of sheep.20,27 Furthermore, the cellular recruitment was not consistent with the
predominantly neutrophilic inflammation that occurs hours after pulmonary
lipopolysaccharide instillation in rats.15 In previous work, the administration of human VEGF
either as a recombinant protein or by adenoviral-mediated gene transfer showed functional
activity (e.g., angiogenesis or other vascular changes) in the lamb model.12,17 However, the
recombinant human VEGF (rhVEGF) was administered by IV during gestation and not in the
airways, whereas the instillation of adenovirus-mediated VEGF gene transfer was not
morphologically evaluated for 3 to 4 weeks after administration. Thus, it is not feasible to
directly compare the monocyte/macrophage recruitment or the lack of vascular alteration seen
in this current study with those earlier experiments.
This experiment suggests that the monocytic recruitment seen in these lambs was a direct result
of VEGF administration. Monocyte (macrophage) recruitment and activation by VEGF has
been reported in the literature. For example, VEGF expression is associated with macrophage
infiltration in human-breast carcinoma.19 Another study showed rhVEGF-induced monocyte
adhesion and transmigration through human umbilical vein endothelial cells, and this was
dependent on the interaction of monocyte β2-integrin with endothelial intercellular adhesion
molecule-1.14 Recently, VEGF-mediated chemotaxis of monocytes/macrophages was shown
to be critical for corneal neovascularization during inflammation.9 At least 2 of the VEGF
receptors, VEGFR-1 (FLT-1) and VEGFR-2 (FLK-1), have been implicated in mediating this
monocyte/macrophage activation and recruitment.7,29 Alternatively, the VEGF treatment may
indirectly induce cellular recruitment through endothelial upregulation of chemokines,
including monocyte chemotactic protein-1.28,31 Regardless of the mechanism, this study
suggests that in the lamb model VEGF deposition in the lung can cause an acute dose-dependent
recruitment of monocytes and macrophages.
The concentrations of VEGF deposited in this study ranged from 0.0005 to 0.05 mg/ml (× 10
ml) compared with the previous preterm mouse study, which used a concentration as high as
0.2 mg/ml (× 5 µl).8 The preterm mice had no monocyte/macrophage recruitment, even though
a higher VEGF dose was used. This suggests that the total amount of VEGF administered may
be more important than the solution concentration. Alternatively, this could merely reflect
inherent physiologic differences in the animal models. While both the mouse and the lamb
have been used for perinatal pulmonary research, there are distinct differences between the
species regarding lung development. For instance, lambs and humans enter the alveolar stage
of lung development late in gestation, whereas rodents begin alveolar development postnatally.
2,3,16 The stage of growth is relevant as developing alveolar epithelium is suggested to play
an important role in regulating VEGF activity and alveolar capillary development.4 Although
the duration of exposure did not appear to have significant impact in this study, recent work
using transgenic mice with inducible VEGF expression showed that chronic VEGF expression
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can cause pulmonary hemorrhage, hemosiderosis, and increased perinatal mortality.18 Future
efforts should further define the role of duration on cellular recruitment and lesions formation.
In conclusion, this study shows that airway deposition of VEGF in neonatal lambs causes
pulmonary monocyte recruitment, with severe microscopic and gross lesions at high dosages.
The VEGF-induced recruitment of monocytes/macrophages warrants caution and the need for
further research in multiple species (rodent and nonrodent) before application to pediatric
patients.
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Fig. 1.
Lungs, lamb. Sections of control lungs lacked cellular infiltrate. Bar = 200 µm.
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Fig. 2.
Lungs, lamb. Alveolar lumens and septa had severe cellular infiltration after high dose (0.05
mg/ml) VEGF treatment. Bar = 200 µm.
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Fig. 3.
Lungs, lamb. The cellular infiltration in VEGF-treated lungs was composed primarily of
monocytes/macrophages. Bar = 50 µm.
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Table 1
Experimental design, gross lesion, and microscopic monocyte/macrophage recruitment scores in neonatal lambs
after administration of VEGF.
Lamb
No.Treatments, hour*
Gross Lesion
Score†
Monocyte/
Macrophage
Recruitment
Score‡
Saline solution
1 16 − 1
2 24 − 1
3 32 − 1
VEGF (0.0005 mg/ml)
4 16 − 2
5 24 − 2
6 32 − 2
VEGF (0.005 mg/ml)
7 16 − 2
8 16 + 1.5
9 24 − 2.5
10 24 − 2
11 24 + 2
12 32 + 2.5
13 32 ++ 3
VEGF (0.05 mg/ml)
14 16 + 3.5
15 24 + 3
16 32 +++ 4
BSA (0.1 mg/ml)
17 32 − 1
18 32 − 1
*
Lambs were given 10 ml of sterile saline solution, BSA, or VEGF for a duration of 16, 24, or 32 hours.
†
Lungs lesions were scored (see Materials and Methods section) at necropsy as follows: no lesions (−), mild (+), moderate (++), severe (+++); VEGF
dose had a significant effect on gross lesion score (P < .0047).
‡
Average monocyte/macrophage infiltration was scored as follows: normal limits (1), mild (2), moderate (3), severe (4); VEGF dose had a significant
effect on monocyte/macrophage infiltration (P < .0001).
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